BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17851880)

  • 1. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
    Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP; Chroni E
    Acta Oncol; 2007; 46(8):1131-7. PubMed ID: 17851880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy.
    Argyriou AA; Polychronopoulos P; Koutras A; Xiros N; Petsas T; Argyriou K; Kalofonos HP; Chroni E
    Eur J Cancer Care (Engl); 2007 May; 16(3):231-7. PubMed ID: 17508942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
    Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
    Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
    Land SR; Kopec JA; Cecchini RS; Ganz PA; Wieand HS; Colangelo LH; Murphy K; Kuebler JP; Seay TE; Needles BM; Bearden JD; Colman LK; Lanier KS; Pajon ER; Cella D; Smith RE; O'Connell MJ; Costantino JP; Wolmark N
    J Clin Oncol; 2007 Jun; 25(16):2205-11. PubMed ID: 17470850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PSK decreased FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer].
    Shibata M; Shimura T; Nishina Y; Gonda K; Matsuo S; Abe H; Yajima Y; Nakamura I; Ohki S; Takenoshita S
    Gan To Kagaku Ryoho; 2011 May; 38(5):797-801. PubMed ID: 21566440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
    Matsumoto S; Nishimura T; Kanai M; Mori Y; Nagayama S; Kawamura J; Nomura A; Miyamoto S; Kitano T; Ishiguro H; Yanagihara K; Teramukai S; Sakai Y; Chiba T; Fukushima M
    Chemotherapy; 2008; 54(5):395-403. PubMed ID: 18781065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
    Liu ZF; Guo QS; Zhang XQ; Yang XG; Guan F; Fu Z; Wang MY
    Am J Clin Oncol; 2008 Jun; 31(3):259-63. PubMed ID: 18525305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
    Figer A; Perez-Staub N; Carola E; Tournigand C; Lledo G; Flesch M; Barcelo R; Cervantes A; André T; Colin P; Louvet C; de Gramont A
    Cancer; 2007 Dec; 110(12):2666-71. PubMed ID: 17963264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
    Briani C; Argyriou AA; Izquierdo C; Velasco R; Campagnolo M; Alberti P; Frigeni B; Cacciavillani M; Bergamo F; Cortinovis D; Cazzaniga M; Bruna J; Cavaletti G; Kalofonos HP
    J Peripher Nerv Syst; 2014 Dec; 19(4):299-306. PubMed ID: 25582667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX).
    Jung KH; Kil SY; Choi IK; Seo JH; Shin C; Kim YS; Kim JH
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1181-2. PubMed ID: 17044215
    [No Abstract]   [Full Text] [Related]  

  • 14. [Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
    Kato T; Matsunaga Y; Motokawa S; Nakagaki S; Nagata N; Yoshida T; Muramatsu T; Kimura H; Ohashi Y; Kudou Y; Shino M; Yamazaki K; Boku N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1697-702. PubMed ID: 19838030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
    Kuebler JP; Colangelo L; O'Connell MJ; Smith RE; Yothers G; Begovic M; Robinson B; Seay TE; Wolmark N
    Cancer; 2007 Nov; 110(9):1945-50. PubMed ID: 17853393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Zhao JG; Qiu F; Xiong JP; Zhang L; Xiang XJ; Yu F; Yan J; Zhan ZY; Feng M
    Anticancer Drugs; 2009 Apr; 20(4):281-6. PubMed ID: 19247179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
    Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin-related acute disseminated intravascular coagulation syndrome in a patient with metastatic colon cancer.
    Malkhasyan K; Halene S; Lacy J
    Clin Colorectal Cancer; 2015 Mar; 14(1):e9-e12. PubMed ID: 25446051
    [No Abstract]   [Full Text] [Related]  

  • 20. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
    Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
    Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.